The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Covering sudden costs requires a quick plan: balance cash, credit options, and smart cuts to stay on track.
13,220 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Executives gathered at the Fortune CEO Initiative dinner to debate debt risks, global diplomacy, and the role of busi...
Investors are asking if this lucid make investors wealthier. The answer lies in Lucid's disciplined path to scale, ma...
Investors are looking at SMH with fresh eyes as AI infrastructure expands. This article explains why a bold predictio...
You don't need a big windfall to start investing for the long term. With $100, you can assemble a simple, durable Van...
When insider moves hit the headlines, investors seek clarity. This piece breaks down what it means when the holdings ...
Intel stock popped today as optimism about AI demand and data-center upgrades fed investor enthusiasm. This article b...
As a CFP®, I see recurring investing mistakes that erode gains. This practical guide shows how to spot them and turn ...
In a historic U.S. mortgage milestone, Coinbase and Better Home & Finance launch the first conforming crypto-backed p...
A Russian actor allegedly used forged ties to the Astor name to extract roughly $450 million from a Mexican billionai...
Investing hinges on leadership as much as numbers. This guide dives into how Josh D'Amaro's new approach could influe...
A new NRMLA webinar explores how caregiving and intergenerational concerns influence reverse mortgage choices, offeri...